WO2003013504A1 - Diacyglycerol mimetics and methods of using the same as protein kinase c alpha activators and apoptosis inducers - Google Patents
Diacyglycerol mimetics and methods of using the same as protein kinase c alpha activators and apoptosis inducers Download PDFInfo
- Publication number
- WO2003013504A1 WO2003013504A1 PCT/US2002/025088 US0225088W WO03013504A1 WO 2003013504 A1 WO2003013504 A1 WO 2003013504A1 US 0225088 W US0225088 W US 0225088W WO 03013504 A1 WO03013504 A1 WO 03013504A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- composition
- subject
- groups
- compounds
- Prior art date
Links
- 0 CC(CN(*)O)(C1)OC(*)C1=* Chemical compound CC(CN(*)O)(C1)OC(*)C1=* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
Definitions
- the present invention in general relates to diacylglycerol analogs containing an N-OH group, pharmaceutical compositions comprising such analogs, and methods of using the same.
- PKC Protein kinase C
- DAG diacylglycerol
- the PKC family comprises at least 10 related kinases with differential expression, subcellular distribution, and biochemical regulation.
- PKC isozymes have been classified into 3 subclasses according to their structure and regulation: "classical” or calcium- dependent (“cPKCs” ⁇ , ⁇ , and ⁇ ), “novel” or calcium-independent (“nPKCs” ⁇ , ⁇ , ⁇ , and ⁇ ) and "atypical” PKCs. While aPKCs are insensitive to DAG and the phorbol esters, cPKCs and nPKCs bind phorbol esters with high affinity in the presence of phospholipids as cofactors. PKC isozymes are subject to 17, regulatory mechanisms and can have either overlapping or opposite biological functions. Jaken, S., Current Opinion in Cell Biology, 1996, 8, 168-173.
- Synthesis of DAG compounds is generally easier than synthesis of phorbol esters due, at least in part, to the presence of multiple chiral centers in the phorbol esters.
- previously known DAG analogs do not show sufficient pharmaceutical potency as compared to phorbol esters to be useful as PKC activators and/or apoptosis inducers.
- Introduction of certain structural changes to particular DAG compounds has been shown to increase binding affinities (K;) of DAG-lactones to PKC in in vitro competition binding assays. Marquez, et al., Pharmacol. Ther., 1999, 82(2-3) 251-61.
- the first structural change involved a cyclization of a DAG compound to form a DAG- lactone, which led to an order of magnitude decrease in Ki (10-fold increase potency).
- Ki 10-fold increase potency
- Tethering a hydrophobic alkyl chain as an ⁇ -alkylidene substituent to the lactone further provided an additional order of magnitude decrease in Ki (10-fold increase potency). Id. While these structural changes have created somewhat effective in vitro PKC activators, there is a need for the synthesis of DAG-analogs having superior in vivo efficacy and superior apoptopic inducing abilities.
- the present methods may be utilized to activate an apoptopic response in a human or animal by administration of a composition comprising an effective amount of an active DAG analog of the new class of DAG-lactone compounds.
- a composition comprising an effective amount of an active DAG analog of the new class of DAG-lactone compounds.
- methods for inducing apoptosis by exposing cells to an apoptotic inducing amount of one or more of the newly created DAG-lactone mimetics or pharmaceutically acceptable salts of such compounds.
- the new DAG-mimetic compound satisfies general formula (1) as follows:
- Ri, R 2 , R 3 , and R 4 are independently selected from the group consisting essentially of hydrogen, oxygen, nitrogen, hydroxyls, halogens, branched or unbranched, substituted or unsubstituted, aliphatic groups, heteroatom (e.g., O, S, N, hydroxyls, halogens) substituted aliphatic groups, aromatic groups, and all major functional groups.
- Ri is O and R 3 is a hydroxyalkyl such as CH 2 OH.
- R 2 is an alkylidene group derived from an aldehyde and R 4 is an alkyl group derived from an acid chloride.
- the size of the lactone ring may be varied by either increasing or decreasing the ring size.
- Ri, R 2 , R 3 , and R 4 when comprising carbon chains or rings, comprise groups of carbon chains or rings of 12 carbon atoms or less.
- Another embodiment comprises DAG-lactone mimetics that satisfy general formula (2) as follows:
- R , R 3 , and R 4 are as set forth above in relation to formula (1).
- Another embodiment comprises DAG-lactone mimetics that satisfy general formula (3) as follows:
- lactone rings of all embodiments may be varied in size.
- DAG-analogs (and variations of the same) satisfy general formula (5) as follows:
- R 2 are independently selected from the group consisting essentially of branched or unbranched, substituted or unsubstituted, aliphatic groups, substituted aliphatic groups, and aromatic groups, more particularly, hydrogen, hydroxyls, halogens, branched or unbranched, substituted or unsubstituted alkyls, alkenyls, alkynyls, alkoxies, amino groups, or aryl groups that may also, for example, optionally be substituted with one or more alkyl, alkenyl, alkynyl, amino groups, hydroxyl groups, or alkoxy groups or wherein, R is either (CH 3 ) 3 C or ( - Pr) 2 CHCH 2 or wherein R 2 is either CH 2 CH( -Pr) 2 or CH 2 CH[CH 2 (t-Pr)] 2 .
- DAG mimetic compounds disclosed herein comprise compounds 2a, 2b, 3a, 3b, 4a, 4b, 7a, 7b, 8a, 8b (as in the Schemes shown below) that satisfy formulas 2a, 3a, 3b, 4a, 4b, 7a, 7b, 8a, 8b as follows:
- the new DAG-lactone analog compounds will effectively bind to PKC and induce apoptosis by possessing binding affinities for PKC ("K;”) under about 12 nM, low enough lipophilicity values (“Log P") ca. 3.6 that are still compatible with high binding affinities and sufficient apoptotic-inducing activity in the low micromolar range as would be measured in an in vitro model system (see FIGS. 2 A and 2B).
- compositions that include one or more of the new compounds described above, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers. Further, it is to be understood that the compounds disclosed herein are shown generally above, but include all other compounds that are members of the genus described by such general formulas.
- FIG. 1 is a table summarizing actual or expected log P and Ki values for particular embodiments of the new DAG-lactone compounds disclosed herein.
- FIGS. 2A and 2B illustrate particular DAG-lactone compound embodiments' actual or expected efficacy at inducing apoptosis in LNCaP cells.
- LNCaP cells are treated with different compounds for 1 hour. Apoptosis is determined 24 hours later.
- Concentration-dependence analysis is of actual or expected apoptosis induced by phorbol esters (PMA 4 ⁇ -PMA, and PDBu), OAG, and DAG-lactones.
- the incidence of apoptosis in each preparation is analyzed by counting 500 cells and determining the percentage of apoptotic cells. Results are the actual or expected mean value results ⁇ S.E. of 3 independent experiments.
- FIGS. 3 A and 3B illustrate the expected inhibition of DAG-lactones-induced apoptosis by a caspase inhibitor and Bcl-2 over expression using an embodiment of the new class of DAG-lactone compounds.
- LNCaP cells are treated with 100 nM PMA (open bars), 10 ⁇ M compound 6a (solid bars) or vehicle (hatched bars) in the absence or presence of a pan-caspase inhibitor z-NAD (50 ⁇ M), to be added 1 hour before and during treatment.
- L ⁇ CaP cells over expressing Bcl-2 (L ⁇ CaP- ⁇ eo/Bcl-2) or ock- transfected cells (LNCaP-Neo) are treated with 100 nM PMA (open bars), 10 ⁇ M compound 6a (solid bars) or vehicle (hatched bars). Cells are to be collected 24 hours later and stained with DAPI. The incidence of apoptosis expected in each preparation is to be analyzed by counting 500 cells and determining the percentage of apoptotic cells. The expected results are reported as the expected mean ⁇ S.E. of 3 independent experiments.
- FIGS. 4A and 4B illustrate the expected effect of a PKC inhibitor (GF 109203X) using embodiments of the new class of DAG-lactone compounds.
- LNCaP cells are to be treated with vehicle, 100 nM PMA, 10 ⁇ M compound 6a and were treated with vehicle, 100 nM PMA 10 ⁇ M compound 3a either in the absence or presence of 5 ⁇ M GF 109203X, added 1 hour before and during the treatment with DAG-lactones or PMA.
- Cells were (or "are” in the case of compound 6a) collected 24 hours after treatment and stained with DAPI.
- the incidence of apoptosis in each compound 3a preparation was analyzed by counting 500 cells and determining the percentage of apoptotic cells.
- Results are the mean ⁇ S.E.
- the expected incidence of apoptosis in each compound 6a preparation will be analyzed by counting 500 cells and determining the percentage of apoptotic cells.
- Expected results are the expected mean ⁇ S.E. of 3 independent experiments. After staining with propidium iodine, DNA content was (or "are" in the case of compound 6a) analyzed by flow cytometry.
- FIGS. 5 A and 5B illustrate the expected effect of Go6976 and rottlerin.
- LNCaP is treated with increasing concentrations of either G ⁇ 6976 or rotterlin, 1 hour before and during PMA or compound 6a treatment. Twenty-four hours later cells treated with Go6976 and rottlerin are stained with DAPI. The incidence of apoptosis in each Go6976 and rottlerin preparation is then assessed by county 500 cells and determining the percentage of apoptotic cells. The expected results for compound 6a treatment are also listed.
- Go6976 or rotterlin results are mean ⁇ S.E. of 3 independent experiments. Open bars, 100 nM PMA; solid bars, and the expected results for 10 ⁇ M compound 6a; hatched bars, vehicle.
- FIGS. 6A and 6B illustrate the expected effects of over expression of PKC ⁇ or PKC ⁇ on compound 6a and PMA-induced apoptosis.
- LNCaP cells are infected with PKC ⁇ AdV (open bars), PKC ⁇ AdN (solid bars) or LacZAdV (hatched bars) at different MOIs (1-30 pfu/cell) for 14 hours. Twenty-four hours later cells were treated with either 3nM PMA or are treated with 1 ⁇ M compound 6a for 1 hour. Cells are collected 24 hours later and stained with DAPI. The incidence of actual (or expected in the case of compound 6a) apoptosis in each preparation was (or is) analyzed by counting 500 cells and determining the percentage of apoptotic cells. Results and expected results are presented as the mean ⁇ S.E. of 3 independent experiments.
- FIG. 7 illustrates the expected results of competition of [ 3 H]PDBu binding to
- PKC ⁇ by compound 6a Binding to recombinant PKC ⁇ is to be performed using a fixed concentration of [ 3 H]PDBu ([ 3 H] phorbol 12, 13-dibutyrate) (5nM) in the presence of 100 ⁇ g/ml phosphatidylserine, and six increasing concentrations (in triplicate) of non- radioactive compound 6a. Each point represents the expected mean value result ⁇ S.E.
- FIG. 8 illustrates expected activation of PKC ⁇ and PKC ⁇ by compound 6a.
- PKC ⁇ and PKC ⁇ activities are to be assayed in the presence of 100 ⁇ g/ml phospholipid vesicles (20% phosphatidylserine/80% phosphatidylcholine) and increasing concentrations of compound 6a.
- Expected results are expressed as percentages of maximum activation to be observed with 1 ⁇ M PMA (dotted line), and represent the expected mean value result ⁇ S.E.
- FIGS. 9A-9D illustrate the expected translocation of PKC isozymes by DAG- lactones. Actual quantitative changes in the fluorescent distribution of GFP-PKC ⁇ and GFP-PKC ⁇ at the plasma membrane (open symbols) and nuclear membrane (closed symbols) in response to different doses of PMA and expected quantitative changes in response to different doses of compound 6a are shown. Results and expected results (for compound 6a) are expressed as changes in the ratios of plasma membrane and nuclear membrane translocation as a function of time.
- a “pharmaceutical agent” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject. All chemical compounds include both the (+) and (-) stereoisomers, as well as either the (+) or (-) stereoisomer unless otherwise indicated.
- Diacylglycerol typically refers to compounds satisfying the following generic chemical structure:
- R ⁇ and R 2 are usually, but not necessarily, aliphatic, alicyclic, or aromatic groups.
- a diacylglycerol (DAG) "analog” refers to a synthetic chemical compound having a diacylglycerol backbone (i.e., side groups have been added or such groups have been deleted from the parent diacylglycerol structure).
- the DAG analogs differ in structure from natural diacylglycerol such as by a difference in the length of an alkyl chain, a molecular fragment, by one or more functional groups, or a change in ionization.
- Diacylglycerol analogs generally are not naturally occurring compounds. That is, diacylglycerol analogs generally cannot be enzymatically or nonenzymatically formed in the body.
- apoptosis refers to programmed cell death as signaled by the nuclei in normally functioning human and animal cells when age or state of cell health and condition dictates.
- aliphatic refers to any organic compound of hydrogen and carbon characterized by a straight chain of the carbon atoms, including alkanes, alkenes, alkynes, alcohols, dienes, aliphatic cyclic hydrocarbons, and all major functional groups, such as alkyl halides, ethers, aldehydes, ketones, acids, and esters.
- alcohol refers to any member of a class of organic compounds in which a hydroxy (-OH) group has replaced a hydrogen atom of a hydrocarbon.
- the term "acid” refers to a compound capable of transferring a hydrogen atom in solution.
- acyl refers to the general formula RCO, where R may be an aliphatic, alicyclic, or aromatic group.
- alkyl refers to a cyclic, branched, or straight chain alkyl groups containing only carbon and hydrogen, and unless otherwise mentioned contains one to twelve carbon atoms. Groups such as methyl, ethyl, isopropyl (i-Pr) and pivaloyl further exemplify this term. Alkyl groups can either be unsubstituted or substituted with one or more substituents.
- alkyl residue refers to a branched or straight chain alkyl group containing only carbon and hydrogen, and unless otherwise mentioned contains one to twelve carbon atoms. Groups such as methyl, ethyl, n-propyl, isobutyl, pentyl and pivaloyl further exemplify the term. Alkyl groups can either be substituted or unsubstituted.
- lactam refers to an internal cyclic amide.
- lactone refers to an internal cyclic ester
- halogen refers to fluoro, bromo, chloro and iodo substituents.
- a “pharmaceutical agent” or “drug” refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
- the pharmaceutically acceptable salts or carriers of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
- bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxy
- heteroatom refers to an organic compound including any atom other than carbon or hydrogen.
- a "major functional group” is an atom or group of atoms acting as a unit that has replaced a hydrogen atom in a hydrocarbon molecule and whose presence imparts characteristic properties to the molecule.
- alkoxy is an alkyl radical attached to a molecule by oxygen.
- An “acid chloride” is a compound containing the radical -COC1, such as benzoyl chloride.
- An “aldehyde” is a class of organic compounds containing the radical CHO.
- a “mammal” includes both human and non-human mammals. Similarly, the term “subject” includes both human and veterinary subjects.
- an "animal” is a living multicellular vertebrate organism, a category that includes, for example, mammals and birds.
- Optical rotations were or are recorded on a Perkin-Elmer model 241 polarimeter at room temperature with a path length of 1 dm.
- Positive ion fast-atom bombardment mass spectra (FAB-MS) were or are to be obtained on a VG 7070E mass spectrometer at an accelerating voltage of 6kN and a resolution of 2000.
- Glycerol was or is used as the sample matrix and ionization was or is effected by a beam of xenon atoms. Elemental analyses were performed by Atlantic Microlab, Inc., Atlanta, GA.
- Steps a and b as shown in Scheme 1 below, are described further in the Encyclopedia of Reagents for Organic Synthesis, 8, 1995, 5364, Leo Paquette, John Wiley & Sons, incorporated herein by reference.
- Compounds 22a and 22b are treated with O-benzyl-N-pivaloyl-hydroxylamine in the presence of K 2 CO 3 and acetone at room temperature to form compounds 23a and 23b to have benzyl protecting groups such that the N-alkylation compounds are formed rather than O-alkylation compounds (step c in Scheme 1).
- Step c in Scheme 1 is also described, e.g., in Maurer et al., /. Am. Chem.
- reagents employed in Scheme 1 above are as follows: (a) eerie ammounium nitrate (CAN), CH 3 CN/H 2 0, 4/1, at 0 ° C; (b) Ph 3 P, CBr 4 , DMF, at room temp.; (c) K 2 CO 3 , acetone, at room temp.; (d) [H2], Pd(OH) 2 , cyclohexane.
- the reagents utilized in Scheme 2 were as follows: (a) BC1 3 , CH 2 C1 2 , at about -78 ° C; (b) MsCl, Et 3 N, CH 2 C1 2 ; (c) NaN 3 , DMF, at 100 ° C; (d) LiHDMS, THF, at about - 78 ° C, [( -Pr)CH 2 ] 2 CHCH 2 CHO; (e) MsCl, Et 3 N, CH 2 C1 2 , DBU; (f) H 2 , Lindlar catalyst, EtOH; (g) (CH 3 ) 3 COCl, Et 3 N, CH 2 C1 2 ; and (h) CAN, CH 3 CN-H 2 O (4:1), at 0 °C.
- Reagents (a) LiHDMS, THF, -78 ° C, R 2 CHO; (b) MsCl, Et 3 N, CH 2 C1 2 , DBU; (c) BC1 3 , CH 2 C1 2 , -78 ° C; (d) RiCO 2 Cl, Et 3 N, DMAP, CH 2 C1 2 ; (e) CAN, CH 3 CN-H 2 O (4:1), 0°C.
- ID 50 values are determined from the competition curve (a curve identical to that shown in FIG. 7) and the K ⁇ for the competing ligand is calculated from the IDso by using the relationship wherein, K is the dissociation constant for [ 3 H]PDBu and L is the concentration of free [ 3 H]PDBu at the ID 50 .
- PKCs used in these assays are generated by baculovirus infection of Sf9 insect cells and subsequent purification, as described in Kazanietz, et al., Mol. Pharmacol., 1993, 44, 298-307, which is incorporated herein by reference. As can be seen in FIG.
- log P The octanol/water partition coefficient (log P) is calculated according to the fragment-based program described in KOWWIN 1.63. Meylan, et al., J. Pharm. Sci., 1995, 20:84, which is incorporated herein by reference.
- the lipophilicity value is correlated with the corresponding PKC binding affinity by plotting log(l/K versus log P.
- Control of lipophilicity is important for several reasons.
- a compound with too high of an affinity for lipids will likely become trapped in the cellular membrane and be unable to interact effectively with PKC.
- a compound with too low of an affinity for lipids will likely not even enter the cell.
- Compounds with a high log P are very oily, are, thus, not water-soluble and therefore make poor pharmaceutical formulations.
- Substitution of an NOH group for the O at the X position of the structure shown in Formula 5 above is expected to lead to a drop in the log P values by over two full units, from about 5.89 to 3.58.
- the log P values for these compounds are expected to range from approximately 7 to 3.5. The lower the log P values the better as long as the compound maintains good binding affinity. Superior results are expected to be achieved at a log P value of about 3.5 and no lower than about 3. For compound 6a, a log P value of 3.6 is optimal but other log P values are acceptable.
- DAPI 6-diamidino-2-phenylindole
- Cell culture reagents and media may be purchased from Life Technologies, Inc. of Gaithersburg, Maryland. Cells are trypsinized, mounted on glass slides, fixed in 70% ethanol, and stained for 20 min with 1 mg/ml DAPI.
- Apoptosis is characterized by chromatin condensation and fragmentation when examined by fluorescence microscopy. The incidence of apoptosis in each preparation is analyzed by counting 500 cells and determining the percentage of apoptotic cells as described in Fujii, et al., J. Biol. Chem., 2000, 275, 7574-7582, which reference is incorporated herein by reference.
- DNA laddering is measured using the Apoptotic DNA-Ladder kit available from Boehringer Mannheim Corp (Indianapolis, IN).
- Apoptotic DNA-Ladder kit available from Boehringer Mannheim Corp (Indianapolis, IN).
- flow cytometry analysis cells are fixed in 70% ethanol and re-suspended in PBS containing propidium iodide (1 mg/ml) and RNase (40 ⁇ g/ml). Cell cycle progression and apoptosis are analyzed in an EPICS XL flow cytometer (Coulter Corp, Hialeah, FL). For each treatment 7,500 events were or are recorded.
- Human prostate cancer cell line LNCaP is purchased from the American Type Culture Collection of Rockville, Maryland.
- the LNCaP cells are cultured in RPMI 1640 medium supplemented with 10% fetal bovine_serum (FBS), 100 units/ml penicillin and 100 ⁇ g/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere.
- the LNCaP cells are treated with different synthetic DAG-mimetics at a single concentration (10 ⁇ M) for 1 hour, and apoptosis is assessed 24 hours later by counting the number of apoptotic cells after DAPI staining. After such time, a maximum apoptotic response may be observed following PKC activation.
- Replication-deficient adenoviruses (AdV) are used for individual PKC isozymes.
- PKC ⁇ AdN and PKC ⁇ AdN are produced as described in the Fuji article referenced above.
- Kinase inactive PKCs are generated to an Arg to Lys substitution at the ATP-binding site of the catalytic domain, and the corresponding AdVs are then generated as described in Onba et al, Mol. Cell Biol., 18, 1998, 5199- 5207, which is incorporated herein by reference.
- AdVs are amplified in HEK 293 cells using standard techniques. Titers of viral stocks are normally higher than 1 x 10 9 pfu/cell. The absence of wild type AdV is confirmed by PCR using primers for the El region. An AdV for the LacZ gene (LacZAdN) is used as a control.
- Subconfluent LNCaP cells in 6- or 12-well plates are infected with AdVs for 14 hours at multiplicities of infection (MOIs) ranging from 1 to 30 pfu/cell (in RPMI 1640 medium supplemented with 2% FBS). Following infection, the media is replaced with fresh RPMI 1640 medium supplemented with 10% FBS and the cells are grown for an additional 24 hours. Maximum expression of PKC isozymes after AdV infection is to be achieved with this protocol.
- MOIs multiplicities of infection
- Synthetic DAG-lactones PMA or vehicle (ethanol), are added for 1 hour at different concentrations to either non-infected cells or to cells infected with different AdVs. After treatment, cells are grown in RPMI 1640 supplemented with 10% FBS for 24 hours. PKC inhibitors (GF109203X, Go6976 or rotterlin) or the pan-caspase inhibitor z-VAD are added 1 hour before and during DAG-lactones or PMA treatment.
- Cells are harvested and lysed in a buffer containing 50mM Tris-HCI, pH 6.8, 10% glycerol, 2% SDS, and 5% ⁇ -mercaptoethanol. Equal amounts of protein (10 ⁇ g) are subjected to SDS-PAGE and transferred to nitrocellulose membranes. Membranes are blocked with 5% non-fat milk and 0.1% Tween 20 in phosphate-buffered saline (PBS), and then incubated with a monoclonal anti-PKC ⁇ antibody (1:3000, UBI, Lake Placid, NY) or a polyclonal anti-PKC ⁇ antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA).
- PBS phosphate-buffered saline
- Membranes are washed three times with 0.2% Tween 20/PBS and incubated with anti-mouse or anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:10,000, Bio-Rad Laboratories, Hercules, CA). Bands are visualized by the enhanced chemiluminescense (ECL) Western blotting detection system (Amersham Pharmacia Biotech, Arlington Heighs, IL).
- ECL enhanced chemiluminescense
- LNCaP cells are transfected with vectors encoding for GFP fusion proteins for PKC ⁇ ahd PKC ⁇ using Lipofect AMESfE PLUS (Life Technologies, Inc.) according to the manufacturer's instructions. The fluorescence becomes detectable 24 hours after transfection, and all experiments are performed 3 days after transfection. Prior to observation, transiently tranfected LNCaP cells are washed twice with standard medium (Dulbecco's modified Eagle's medium without phenol red supplemented with 1% FBS) pre-warmed to 37°C. All PKC activators are diluted to specified concentrations in the same medium, and the final concentration of solvent (ethanol) is preferably less than 0.01%.
- solvent ethanol
- the Bioptechs Focht Chamber System (FCS2) is inverted and attached to the microscope stage with a custom stage adapter.
- the cells cultured on a 40-mm round coverslip are introduced into a chamber system that is connected to a temperature controller set at 37°C, and a medium is perfused through the chamber with a model P720 microperfusion pump (Instech, Plymouth Meeting, PA).
- the perfustate to the chamber is changed to that containing the specified ligand for PKC and sequential images of the same cell are then collected at 1 minute intervals using LaserSharp software through a BioRad MRC 1024 confocal scan head mounted on a Nikon Optiphot microscope with a planapochromat lens.
- Excitation at 488 nm is provided by a krypton-argon gas laser with a 522/32 emission filter for green fluorescence.
- the present invention includes a treatment for cancer in a subject such as an animal, for example a rat or human, by inducement of apoptosis.
- the method includes administering one or more of the compounds of the present invention, or a combination of one or more of the compounds and one or more other pharmaceutical agents, to the subject in a pharmaceutically compatible carrier.
- the administration is made in an amount effective to inhibit the development or progression of cancer, specifically prostate cancer without excluding and other types of malignancies.
- the treatment can be used prophylactically in any patient in a demographic group at significant risk for such diseases, subjects can also be selected using more specific criteria, such as a definitive diagnosis of the condition.
- the vehicle in which the drug is delivered can include pharmaceutically acceptable compositions of the drugs, using methods well known to those with skill in the art. Any of the common carriers, such as sterile saline or glucose solution, can be utilized with the drugs provided by the invention.
- Routes of administration include but are not limited to oral and parenteral routes, such as intravenous (iv), intraperitoneal (ip), rectal, topical, ophthalmic, nasal, and transdermal.
- the drugs may be administered in a suitable manner now known or later developed, e.g., orally or intravenously, in any conventional medium.
- intravenous injection may be by an aqueous saline medium.
- the medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like.
- Embodiments of other pharmaceutical compositions can be prepared with conventional pharmaceutically acceptable carriers, adjuvants and counterions as would be known to those of skill in the art.
- the compositions are preferably in the form of a unit dose in solid, semi-solid and liquid dosage forms such as tablets, pills, powders, liquid solutions or suspensions.
- the compounds of the present invention are ideally administered as soon as possible after the diagnosis of cancer. For example, once unwanted angiogenesis has been confirmed or the presence of a tumor has been identified, a therapeutically effective amount of the drug is administered to induce apoptosis.
- the dose can be given orally or by frequent bolus administration.
- the subject may then be monitored for signs of induced apoptosis as, for example, shown by a decrease in tumor size
- Therapeutically effective doses of the compounds of the present invention can be determined by one of skill in the art, with a goal of achieving a desired level of apoptosis as illustrated in the foregoing examples and figures.
- the relative toxicities of the compounds make it possible to administer in various dosage ranges.
- compositions are, for example, provided in the form of a tablet containing from about 25 to about 500 mg of the active ingredient, particularly 100 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject being treated.
- the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound, the staging of the existing cancer, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, and severity of the condition of the host undergoing therapy.
- the pharmaceutical compositions can be used in the treatment of a variety of malignancies. Examples of such diseases include all types of cancer, ocular neovascular disease, solid tumor formation and metastasis in solid tumors.
- the present invention also includes combinations of the DAG analogs of the present invention and/or combinations of the same with various other anticancer agents and/or apoptotic inducing compounds.
- administration refers to both concurrent and sequential administration of the active agents.
- the DAG analogs may be combined with phorbol esters for the treatment of cancer or like diseases.
- the DAG analogs of this invention may be used in combination with other forms of cancer therapy, e.g., chemotherapy, radiation therapy, hormonal therapy).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31065601P | 2001-08-06 | 2001-08-06 | |
US60/310,656 | 2001-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013504A1 true WO2003013504A1 (en) | 2003-02-20 |
Family
ID=23203520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/025088 WO2003013504A1 (en) | 2001-08-06 | 2002-08-06 | Diacyglycerol mimetics and methods of using the same as protein kinase c alpha activators and apoptosis inducers |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003013504A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115611751A (en) * | 2022-11-08 | 2023-01-17 | 四平欧凯科技有限公司 | Preparation method of tris (hydroxymethyl) aminomethane |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294573B1 (en) * | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
-
2002
- 2002-08-06 WO PCT/US2002/025088 patent/WO2003013504A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294573B1 (en) * | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115611751A (en) * | 2022-11-08 | 2023-01-17 | 四平欧凯科技有限公司 | Preparation method of tris (hydroxymethyl) aminomethane |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6174117B2 (en) | Enhanced anti-influenza drugs conjugated with anti-inflammatory activity | |
JP3348859B2 (en) | Protein kinase C inhibitor | |
RU2135515C1 (en) | Cytokines production-inducing carbamates and ureas | |
EP0708085B1 (en) | Antiviral ethers of aspartate protease substrate isosteres | |
US8816122B2 (en) | Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use | |
US10711036B2 (en) | MALT1 inhibitors and uses thereof | |
JP3908270B2 (en) | Acylfulvene analogues and pharmaceutical compositions thereof | |
EP3100723A1 (en) | Opsin-binding ligands, compositions and methods of use | |
SK50793A3 (en) | Method for preparing taxane derivatives, novel derivatives thereby obtained and pharmaceutical compositions containing same | |
CA3061611A1 (en) | Modulators of sestrin-gator2 interaction and uses thereof | |
EP0434365A2 (en) | HIV protease inhibitors useful for the treatment of aids | |
AU2005328327A1 (en) | Novel lipoxygenase inhibitors | |
JPH05507093A (en) | Antiviral and antihypertensive compounds | |
WO2012043891A1 (en) | Agent for treatment of eye diseases | |
WO2019236765A1 (en) | Acylated catechin polyphenols and methods of their use for the treatment of cancer | |
US6335364B1 (en) | Synthetic spiroketal pyranes as potent anti-cancer agents | |
WO2006073456A2 (en) | Anti-coronavirus compounds | |
JP2004527478A (en) | Coumarin compounds as microtubule stabilizers and their therapeutic use | |
JP2000510149A (en) | 8-Hydrocarbon-substituted benzodizosine derivatives, their preparation and their use as modulators of protein kinase C (= PKC) | |
US20110257176A1 (en) | Nitrogen heterocycle derivatives as proteasome modulators | |
WO2003013504A1 (en) | Diacyglycerol mimetics and methods of using the same as protein kinase c alpha activators and apoptosis inducers | |
TW201922690A (en) | Inhibitors of cyclic-AMP response element-binding protein | |
AU4845499A (en) | Synthetic spiroketal pyranes as potent anti-cancer agents | |
JP2001500853A (en) | Pharmaceutical compounds | |
CN116419753A (en) | Heterocyclic compounds as BCL-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |